Research page
GLOW Blend

Specification
| Name | GLOW Blend |
|---|---|
| Catalog sizes | 70 mg |
| Adopted bacteriostatic water | 70 mg + 2.0 mL = 35 mg/mL |
Overview
GLOW Blend is a 70 mg vial. The TRACE label states that mass and does not confirm an internal split. One public guide describes a 70 mg vial as GHK-Cu, BPC-157, and TB-500. TRACE does not adopt that blend. The sheet treats concentration on 70 mg total.
Mechanism under study
The three names that circulate outside TRACE have been studied along different paths: GHK-Cu in matrix and gene-expression models, BPC-157 in animal tissue models, and thymosin β4 (related to what some vials call TB-500) in repair models. None of that identifies the contents of this vial.
What published research has reported
The Pickart and Margolina review (2018) gathers laboratory evidence on GHK-Cu. The BPC-157 work summarized by Sikiric and colleagues is mostly preclinical. This page does not cite a clinical trial of the TRACE GLOW blend.
Composition and mass
70 mg total on the label. Adopted bacteriostatic water: 2 mL, that is 35 mg/mL of the total. That figure does not split the mass among components.
Reconstitution
| mg | mL | mg/mL | |
|---|---|---|---|
| 70 | 2.0 | 35 | In the catalog |
Storage and handling
The same handling as other TRACE lyophilized vials: cool and dry before opening; 2–8 °C after dissolution; do not freeze; 28 days as the use horizon.
Regulatory status
Research material. Not a drug, a supplement, or a food. Not intended to diagnose, treat, cure, or prevent any disease.